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Circulating levels of reactive oxygen species in patients with nonproliferative 
diabetic retinopathy and the infl uence of antioxidant supplementation: 
6-month follow-up
Daniela Domanico, Serena FragioĴ a1, Alessandro Cutini1, Carmela Carnevale2, Luigi Zompatori3, 
Enzo Maria Vingolo1
 IJO_163_14R10
Aims: The aim was to evaluate circulating levels of reactive oxygen species (ROS) and changes in central 
macular thickness (CMT) in patients with nonproliferative diabetic retinopathy (NPDR) after antioxidant 
supplementation. Materials and Methods: A total of 68 patients (68 eyes) with NPDR were enrolled. 
Patients were randomly divided into two groups: Treated with antioxidant supplement (Group A) and 
untreated control group (Group B). Each tablet, for oral administration, containing pycnogenol 50 mg, 
Vitamin E 30 mg and coenzyme Q10 20 mg. CMT and free oxygen radical test (FORT) were analyzed at 
baseline (T0), 3 (T1) and 6 (T2) months in both groups. Results: In Group A, FORT levels and CMT were 
signifi cantly reduced over time (P < 0.001 for both). In Group B, FORT levels were increased (P < 0.001) and 
CMT did not vary signifi cantly (P = 0.81) over 3 time points. Conclusions: This is the fi rst study showing 
the reduction of ROS levels in patients with NPDR thanks to antioxidant therapy. Moreover, our fi ndings 
have suggested also an infl uence on retinal thickness.
Key words: Antioxidant supplementation, diabetes mellitus, free oxygen radicals test, nonproliferative 
diabetic retinopathy, reactive oxygen species
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Diabetes is associated with microvascular complications 
involving the retina, glomerulus and vasa nervorum. 
Hyperglycemia causes abnormalities in the blood flow 
and vascular permeability, due to imbalance between 
vasodilatators (nitric oxide) and vasoconstrictors (angiotensin 
II and endothelin-1) and permeability factors such as vascular 
endothelial growth factor (VEGF).[1]
During diabetes, very low-density lipoprotein, low-density 
lipoprotein and high-density lipoprotein undergo oxidation by 
free radicals. In addition, proteins are also nonenzymatically 
glycated forming advanced glycation end products (AGEs). 
The formation of AGEs increases the production of reactive 
oxygen species (ROS).[2-4] Other pathways contributing in 
ROS production are increased fl ux of glucose through the 
polyol pathway, activation of protein kinase C isoforms 
and hyperactivity of hexosamine pathway. Oxidative 
stress mediated by ROS overproduction is involved in the 
development and progression of endothelial cells and pericytes 
damage in diabetic retinopathy.[5] Thus, the inhibition or 
reduction of oxidative stress may become an important strategy 
for therapy and prevention of diabetic complications.[6-9]
The aim of this study was to assess the efficacy of 
antioxidant dietary supplementation composed by pycnogenol, 
Vitamin E and coenzyme Q10 (CoQ) in reducing the 
ROS levels in patients with nonproliferative diabetic 
retinopathy (NPDR), after 6-month of treatment. Furthermore, 
we also evaluated the possible structural changes of central 
macular thickness (CMT) over time, using spectral domain 
optical coherence tomography (SD-OCT).
Materials and Methods
A total of 68 patients with type 2 diabetes (range: 40–79 years) 
suff ering from mild or moderate NPDR were enrolled. These 
patients were randomly assigned to two age-matched groups: 
Group A receiving antioxidant dietary supplementation 
and untreated control group (Group B). The patients were 
progressively numbered as they presented to our observation, 
we used the online randomization program (hĴ p://www.
graphpad.com/quickcalcs/index.cfm) selecting random 
numbers and then randomly assign subjects to groups.
Each participant gave wriĴ en consent before enrolment 
into the study. Institutional board approval was obtained from 
ethics commiĴ ee of our institution. All procedures adhered to 
the tenets of the declaration of Helsinki.
Eligibility criteria included: Glycosylated hemoglobin levels 
in the normal range (HbA1C level ≤ 6.0%), normal lifestyle 
based on Mediterranean diet, mild-moderate physical exercise, 
abstinence of alcohol and tobacco products, no systemic 
hypertension or dyslipidemia, and no excessive exposure to 
the ultraviolet rays. All the patients had mild or moderate 
NPDR without clinically signifi cant macular edema (CSME), 
according to the Early Treatment Diabetic Retinopathy Study 
protocol.[10,11]
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The patients have received metformin as monotherapy at a 
dose of 1000 mg twice daily. They were treated with the same 
oral hypoglycemic medication for at least 6-month prior to 
study enrollment.
Exclusion criteria were: Presence of coronary artery 
disease (CAD) or family history of CAD, prior treatment with 
Vitamin C or any other antioxidant dietary supplements, 
steroid or nonsteroid anti-infl ammatory drugs, history of 
acute or chronic infections, fever, cancer or organ failure, 
peripheral vascular disease, thrombotic events, urinary 
microalbumin > 300 mg/day. We have also excluded subjects 
with other ocular pathologies, dioptric media opacities, patients 
who had a history of intravitreal injection therapies and 
previous laser treatment, and those with a history of intraocular 
or vitreoretinal surgery within 6-month.
Each tablet (Diaberet®, Visufarma, Rome, Italy) contained 
50 mg of pycnogenol, 30 mg of Vitamin E and 20 mg of CoQ. 
The oral dosage consisted of 1 tablet/day for 6-month.
All patients underwent a complete ophthalmologic 
examination and SD-OCT at baseline (T0), 3 (T1) and 6 (T2) 
months after the antioxidant dietary supplementation. 
Fluorescein angiography (FA) was performed at baseline, to 
exclude the presence of proliferative diabetic retinopathy (PDR). 
A capillary sample was collected for free oxygen radical 
test (FORT) examination at baseline and at months 3 and 6.
Spectral domain optical coherence tomography scans were 
performed with the  Spectralis® HRA+OCT (software version 
5.4.7.0, Heidelberg Engineering, Heidelberg, Germany), in a 
paĴ ern of 20° × 15° (5.8 mm × 4.3 mm) raster scans consisting 
of 19 high-resolution line scans, each composed of 50 averaged 
frame. CMT was measured automatically using standard 
protocols of Heidelberg software. In addition, whenever both 
eyes of a patient were eligible, the right eye was selected as 
the study eye.
Patients were divided into two subgroups according to the 
SD-OCT features: NPDR with diff use retinal thickening (DRT) 
and without (wDRT). DRT is defi ned as increased retinal 
thickness (>200 μm) with reduced intraretinal refl ectivity, 
especially in the outer retinal layers.[12]
SD-OCT examination was performed by the same 
investigator at each follow-up time.
Oxidative stress analysis
The blood levels of ROS were determined using FORT with free 
oxygen radicals monitor and kit (FORM®, CR 2000, Callegari, 
Italy). We used the FORM system to determine the concentration 
of ROS by a specifi c photometric kit of reagents called FORT. 
This is a colorimetric test based on the ability of the transition 
metals, such as Fe2 + or Fe3+, to catalyze the formation of free 
radicals in the presence of hydroperoxides (ROOH) (Fenton 
reaction). Radicals are then chemically trapped in an amine 
derivative.
Fenton reaction
Fe2+ + H2O2 → Fe3+ + OH + OH−.
This chemical reaction leads to the formation of a more 
stable radical colored cation, measured photometrically at 
505 nm using the FORM analyzer. Diff erent degrees of colors 
are directly related to the quantity of radical compounds and 
the oxidative status of the blood sample.
The ROS concentration is expressed using the  free oxygen 
radical test (FORT) units (UF), one UF is approximately equal 
to 0.26 mg/L.[13]
A volume of 20 μl of whole blood was drawn at the morning, 
after an overnight fasting and before the assumption of any 
other medications. The blood samples were allowed to clot for 
30 min, and then centrifuged at room temperature for 10 min. 
Finally, the samples were stored at −20°C until the time of 
assay. The results obtained were expressed in FORT unit.[14]
The patients did not modify their diabetic therapy and 
dietary habits, during the course of the study. HbA1c was 
periodically monitored as an index of glycemic control.
Statistical analysis
Data are expressed as means ± standard deviation. The normality 
of distribution for each variable was analyzed using Shapiro–
Wilk test. Repeated-measures analysis of variance (ANOVA) 
over the 3 times points (baseline, 3 and 6 months) and Bonferroni 
correction for multiple outcomes were used to determine whether 
any diff erences appeared in best-corrected visual acuity (BCVA) 
expressed as logMAR unit. The diff erences between groups were 
calculated using a 1-tailed unpaired t-test or Mann–Whitney 
U-test (nonnormal distribution, Shapiro–Wilk test P < 0.05). 
The Wilcoxon signed-rank and the Friedman tests were used 
to assess the changes over time when data were not normally 
distributed. Spearman’s rank correlation was calculated for 
comparisons. Intraclass correlation (ICCs) were computed to 
estimate the consistency when the same eye is evaluated multiple 
times with SD-OCT. Statistical signifi cance was set at P < 0.05. 
All calculations were carried out with the use of SPSS statistical 
software (version 19; SPSS, Inc., Chicago, IL, USA).
Results
The baseline characteristics of the subjects are summarized 
in Table 1.
None of the patients were lost to follow-up or discontinue 
intervention.
Table 1: Comparison of baseline characteristics between 
patients with (Group A) and without (Group B) antioxidant 
supplementation therapy
Characteristics 34 patients P
Group A Group B
Age (years)
Mean±SD 58.29±12.37 62.29±11.54 0.08a
Gender, n (%)
Male 15 18 0.47b
Female 19 16
Duration of diabetes (years)
Mean±SD 9.2±2.3 8.9±2.5 0.38c
HbA1C (%)
Mean±SD 5.8±1.21 5.6±1.13 0.42c
aUnpaired Student’s t-test, bChi-square test, cMann-Whitney test. 
SD: Standard deviation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
January 2015  9Domanico, et al.: Oxidative stress and retinal thickness changes
In Group A, 3 patients at first follow-up time (8.82%, 
mean time: 7.33 ± 2.51 days) and 5 patients at second 
follow-up (14.70%, mean time: 6.8 ± 2.77 days) have delayed 
their visit. Instead, four patients at fi rst follow-up time (11.76%, 
mean time: 5 ± 4.08 days) and four patients at second follow-up 
time (11.76%, mean time: 5.25 ± 1.70 days) have delayed the 
visit in the Group B.
Mean BCVA was 0.026 ± 0.032 logMAR at baseline, 
0.030 ± 0.032 logMAR at T1 and 0.034 ± 0.033 logMAR at T2 in 
the Group A (ANOVA, F = 0.50, P = 0.60). Moreover, mean BCVA 
was 0.030 ± 0.036 logMAR at baseline, 0.033 ± 0.035 logMAR at 
T1 and 0.037 ± 0.036 logMAR at T2 in the Group B (ANOVA, 
P = 0.29, P = 0.74).
Free oxygen radical test levels were signifi cantly decreased 
over 3 times points in patients under antioxidant therapy, 
whereas significantly increased in the control group. In 
Group A between baseline and T1 there was the greatest 
reduction of free oxygen radical levels (60.11 UF, 95% IC [31.51, 
88.71], P < 0.001 and 0.44 mmol/L H2O2, 95% IC [0.22, 0.66], 
P < 0.001). Instead in Group B the levels of free oxygen radicals 
tended to increase between T1 and T2 (31.47 UF, 95% confi dence 
intervals [CI] [−64.09, 1.15], P < 0.001 and 0.91 mmol/L H2O2, 
95% IC [−4.67, 6.49], P < 0.001) [Table 2 and Fig. 1].
In Group A, CMT was signifi cantly reduced over 3 times 
points, whereas no significant changes were found in 
Group B. The improvement of CMT was greater at T1–T2 time 
interval (−15.44 μm, [95% CI: 3.26, 27.61], P = 0.01), than baseline/
T1 (−8.02 μm, [95% CI: −0.29, 16.35], P = 0.05) [Table 2 and Fig. 1]. 
CMT measurements using SD-OCT, showed an almost perfect 
level of consistency of the ICC coeffi  cient (Group A, ICC: 0.96, 
95% CI: 0.91 − 0.98, P < 0.01; Group B, ICC: 0.97, 95% CI: 0.95, 
0.98, P < 0.01) for each group over time.
No signifi cant correlations were found between the levels 
of FORT and the mean CMT (T0: R = 0.03, P = 0.82; T1: R = 0.04, 
P = 0.78; T2: R = 0.01, P = 0.93).
The DRT subgroups included 8 patients (8 eyes) 
of Group A (54 ± 9.68 years) and 7 patients (7 eyes) of 
Group B (64.28 ± 8.07 years). In the DRT patients under 
antioxidant therapy, the FORT levels were signifi cantly reduced 
over time, but not between T1 and T2 (z = −0.95, P = 0.34), whereas 
CMT was also reduced over time but not between T0 and T1 (z = 
−0.41, P = 0.68). In the control group, FORT levels have increased, 
and CMT has not signifi cantly change over time [Table 3].
The wDRT subgroups consisted of 26 patients (26 
eyes) (54.24 ± 14.72 years) of the Group A and 27 eyes of 
27 patients (61.77 ± 12.36 years) of the Group B. In the wDRT 
Table 2: Outcome variables for the study groups over 3 times points
Variables n=34 eyes
Group A Group B
Baseline 3 months 6 months Baseline 3 months 6 months
FORT-UF 349.88 289.76 259.05 330.41 345.64 377.11
SD 131.72 99.61 47.33 119.44 133.75 119.14
P a <0.001 <0.001
FORT mmol/L H2O2 2.64 2.20 1.96 2.50 2.61 2.81
SD 0.99 0.75 0.35 0.91 1.02 0.92
P a <0.001 <0.001
CMTs-μm 223.97 215.94 200.50 209.35 210.35 209.44
SD 73.95 76.91 56.73 56.97 60.49 56.47
P a <0.001 0.81
All the values are: Means±SD. aFriedman test. UF: FORT units, CMTs: Central macular thickness, SD: Standard deviation, FORT: Free oxygen radical test
Table 3: DRT subgroup analysis, both in antioxidant supplementation (Group A) and control group (Group B) over time
DRT variables n=34 eyes
Group A Group B
Baseline 3 months 6 months Baseline 3 months 6 months
FORT-UF 336.11 292 259 295.71 349.42 326.28
SD 112.97 128.83 54.70 139.28 173.07 123.42
P a 0.001 0.01
FORT mmol/L H2O2 2.55 2.23 1.96 2.24 2.64 2.47
SD 0.85 0.97 0.41 1.05 1.32 0.94
P a 0.001 0.01
CMTs-μm 323.33 320.55 273 301.57 300.71 293.71
SD 75.52 81.61 67.42 63.32 82.14 68.85
P a 0.003 0.65
UF: FORT units, CMTs: Central macular thickness, SD: Standard deviation, FORT: Free oxygen radical test, DRT: Diffuse retinal thickening, aFriedman test
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patients receiving antioxidant therapy both levels of free 
oxygen radicals and CMT were signifi cantly improved over 
time, whereas in the control subgroup the levels of free oxygen 
radicals signifi cantly increased and the CMT did not change 
over time [Table 4, Figs. 2 and 3].
Discussion
In the present study, we have evaluated the efficacy of 
antioxidant dietary supplementation composed by pycnogenol, 
Vitamin E and CoQ in reducing the levels of ROS and the eff ect 
on retinal thickness.
The effi  cacy of oral antioxidant supplements is still unclear. 
Several studies have shown that antioxidant treatment could 
ameliorate endothelial cell dysfunction in diabetic patients.[7,15]
Experimental studies suggest that Vitamin E seems to be 
eff ective in prevents the development and progression of 
diabetic complications. Its action consists in lowering ROS 
concentration, by decreasing lipid peroxidation with less 
eff ect on protein and DNA oxidation.[16,17] The concentration 
of Vitamin E is below standard limits in patients with type 2 
diabetes. Vitamin E supplementation was found to reduce 
glycated hemoglobin both in type 1 and 2 diabetes, especially 
Table 4: wDRT subgroups analysis over 3 times points in both study groups
wDRT variables n=34 eyes
Group A Group B
Baseline 3 months 6 months Baseline 3 months 6 months
FORT-UF 354.84 288.96 259.08 339.40 344.66 390.29
SD 139.66 90.05 45.63 114.99 125.66 116.72
P a 0.009 0.009
FORT mmol/L H2O2 2.68 2.20 1.97 2.57 2.61 2.90
SD 1.05 0.68 0.34 0.87 0.95 0.91
P a 0.004 <0.001
CMTs-μm 188 178 174 185.44 186.92 187.59
SD 24.14 18.22 15.16 17.66 17.85 23.35
P a <0.001 0.61
All the values are: Means±SD. aFriedman test. wDRT: Without diffuse retinal thickening, UF: FORT units, CMTs: Central macular thickness, SD: Standard 
deviation, FORT: Free oxygen radical test
Figure 1: Linear graphs. Graph A shows free oxygen radical test (FORT) levels in the Group A (dashed line) and Group B (continuous line) at 
baseline (T0) 3 months (T1) and 6-month (T2); Graph B shows the changes in central macular thickness (m) in the Group A (dashed line) and 
in the Group B (continuous line) at 3 times points (T0, T1, T2). Graph C shows FORT levels reported as mmol/L in the Group A (dashed line) 
and Group B (continuous line) at 3 times points
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in patients with poor glycated hemoglobin control and low 
levels of Vitamin E.[18-20]
Pycnogenol is a natural pine bark extract with strong 
antioxidant and hypoglycemic properties.[21] Therefore, it is 
also shown to have positive eff ects on diabetic microangiopathy 
and diabetic neuropathy.[22,23]
Coenzyme Q10 is a lipid-soluble molecule derived mainly 
from endogenous synthesis. It plays an essential role as an 
electron carrier in mitochondrial oxidative phosphorylation.[24,25] 
Recent studies have demonstrated that CoQ10 improves 
endothelial function in patients with cardiovascular disease, 
diabetes type 2 and in the experimental model of diabetic 
nephropathy. CoQ might reduce oxidative stress via eff ects 
on the mitochondrial respiratory chain or via recoupling 
endothelial nitric oxide synthase.[26-28]
Our results show that, in the group receiving antioxidant 
therapy the levels of free oxygen radicals and retinal thickness 
were signifi cantly reduced over 3 times points. Conversely, 
in the control group were observed a signifi cant increase of 
oxidative stress parameter s and retinal thickness remained 
essentially unchanged over time.
Our fi ndings suggest that antioxidant supplement may 
improve morphological damage (CMT). Indeed, as reported 
in the literature, ROS promotes breakdown of blood-retinal 
barrier and alters retinal blood flow by modulating the 
production of vasoactive factors, and also upregulates the 
retinal expression of VEGF and adhesion molecules as ICAM-1. 
This cascade of molecular events causes leakage of fl uids into 
the surrounding tissue, which initially accumulate within 
Müller cells. These morphological alterations precede the 
CSME, and they are quantifi able by CMT measurement and 
defi ne the DRT paĴ ern.[6-8,12,29]
In our opinion, the reduction of the ROS levels lead 
downregulation of the growth factors, adhesion molecules, 
and vasoactive substances and consequently, reduction of 
vascular leakage. This is morphologically expressed by the 
CMT reduction that in our study was highly signifi cant in 
patients who had taken antioxidant supplement.
In the subgroup analysis (Group A), the wDRT patients 
also showed FORT levels and CMT  signifi cantly reduced 
over 3 times points.
However, in the DRT subgroup, FORT levels were 
signifi cantly reduced in the fi rst 3 months and remained stable 
over the next months. Instead, the CMT reduction needed 
over 3 months to be signifi cant. Probably, in patients with 
more advanced morphological damage (DRT) 3–6 months 
is the range time necessary to produce a morphological 
improvement (CMT lowering). This occurs only after the 
normalization of ROS levels and the other factors.
This result is confi rmed by previous experimental study 
showing that antioxidant supplementation significantly 
decreases the severity of morphological changes in the RD 
damage after 5 months of administration.[15]
Finally, in our opinion, the measurement of ROS by FORT 
technique is simple, fast and aff ordable as reported in previous 
studies, which assesses oxidative stress in patients with type 2 
diabetes, cardiovascular diseases such as myocardial infarction, 
cancer, and other diseases.[13,14,30-32]
Conversely, the indirect measure of ROS was considered 
studying the eff ects of substances involved in the production 
or elimination of these species using direct chemiluminescence 
and either direct or spin-trap electron paramagnetic resonance 
spectroscopy. A number of reviews have described these 
methods, their logistical constraints, and their use in the 
measurement of ROS.[33,34]
There are some limitations in this study as the small number 
of the sample and the lack of data about the levels of ROS in 
the vitreous.
To our knowledge, this is the fi rst study that reports the 
reduction of ROS in NPDR patients and its infl uence on retinal 
thickness.
In our opinion, antioxidant supplements can be used as a 
complementary therapy alongside traditional medical care, to 
prevent microvascular diabetic complications.
Further studies are needed to evaluate the efficacy of 
antioxidant supplements in larger groups of patients, and 
Figure 3: Spectral domain optical coherence tomography cross-sectional 
scan and average thickness map of Group B patients: (a) Without 
diffuse retinal thickening (DRT) at baseline (upper side) and 6-month 
(lower side) of follow-up (b) patient with DRT at baseline (upper side) 
and 6-month (lower side) of follow-up
a
b
Figure 2: Spectral domain optical coherence tomography cross-
sectional scan and average thickness map of Group A patients: (a) 
Without diffuse retinal thickening (DRT) before (upper side) and 6-month 
(lower side) after the assumption of antioxidant supplement; (b) patient 
with DRT before and after the assumption of antioxidant supplement
a
b
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also in patients with PDR. Moreover, a long-term follow-up is 
necessary to assess the optimal duration of treatmen t.
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